Conducting clinical research studies with
SKILL, KNOWLEDGE and SAFETY.
Call to participate
860.443.4567

Archive for the ‘ Neurology ’ Category

OCD – Obsessive Compulsive Disorder

Thursday, November 19th, 2020

Out of control thoughts, images, and obsessive behaviors and the inability to control these thoughts, images and behaviors. This is a simple explanation of an extremely complicated mental illness – Obsessive Compulsive Disorder, also known as OCD.  This goes far beyond someone’s idea of obsessive cleaning or obsessive handwashing. There are considerable layers to this condition and it can manifest itself in a variety of ways.

Coastal Connecticut Research will be conducting a clinical research trial evaluating a study product for individuals living with OCD.  This condition can affect people of all ages and from all walks of life.   Further details on the trial will be made available as the enrollment period nears.  Those who may wish to learn more about research in this area are welcome to call and speak to a member of the CCRstudies team at (860)443-4567 or email marylou@ccrstudies.com.

Migraine Research

Monday, November 9th, 2020

 

You’re at work – or, at least you’re trying to work thanks to your throbbing head and migraine.  You’re working from home, the pain is so intense your productivity is shot. Does this happen to you?  Migraines can vary in intensity but one thing is for sure, you cannot necessarily proceed as normal  when you get a migraine.  Those living with migraines may experience nausea, sensitivity to lights and sounds, and for many, debilitating pain.

Coastal Connecticut Research is currently enrolled in migraine research trial evaluating the study product and it’s effect on productivity in the workplace.  Have your migraines affected your ability to get the job done?

There is no cost to participate in this clinical research study, no cost for the study product, and all labs, exams and testing are provided at no cost. In addition, reimbursement is available for eligible participants who enroll in the research trial.  Neurologist Dr. Laurence Radin is the principal investigator of the study and Andrea Stewart, APRN is a sub-investigator on the study.  To learn more, call (860)443-4567 or text the keyword CCR to 74121. You can also sign up online at CCRstudies.com to receive further information.

 

Are Migraines Affecting Your Work?

Tuesday, October 20th, 2020

Do migraine headaches affect your work? Do you work at least 20 hours per week?    A migraine research study is being conducted locally at Coastal Connecticut Research in New London, evaluating an investigational migraine medication versus placebo and its effect on workplace productivity.

If you’re an adult living with migraines and you work at least 20 hours per week you may be eligible. There’s no cost for the investigational medicine or placebo and no cost for any study-required procedures. You may also be reimbursed for your time and travel. Neurologist Dr. Laurence Radin and Andrea Stewart, APRN are members of the local research team.

Call 860-443-4567, sign up online at ccrstudies.com or text the keyword CCR to 74121. Call today to learn more about the workplace productivity migraine research study.  860-443-4567.  443-4567.

Alzheimer’s Research Announced in New London

Thursday, October 8th, 2020

New LUCIDITY clinical study to investigate potential treatment for people with Alzheimer’s disease

New London, October 2020- Coastal Connecticut Research has announced the start of patient recruitment for the LUCIDITY study (NCT03446001), a new clinical research study to evaluate an investigational drug in people who are experiencing memory loss, or have been diagnosed with Mild Cognitive Impairment (MCI or MCI-AD), Probable/Early Alzheimer’s disease (AD) or Mild-Moderate AD.

Dr. Laurence Radin will be serving as Principal Investigator of the study. He has served as the study doctor on over 10 clinical research trials for Alzheimer’s disease at Coastal Connecticut Research supported by a team of sub-investigators.

Although it is often accepted that some degree of forgetfulness is a natural part of the aging process, more severe memory loss – especially that which impacts daily life – could be an early sign of AD. Up to one third of people with MCI will go on to develop dementia,1 which affects around 50 million people worldwide.2

Currently, a limited number of approved treatments help with the symptoms of AD, but do not stop the disease from progressing.3 There are many factors and underlying challenges that contribute to the difficulty of developing new treatment options.3 However, rapid advances in our understanding of the underlying causes and risk factors associated with AD have led to new therapeutic targets and approaches.

Recent evidence suggests that Tau tangles are a potential driver in the progressive dementia that characterizes AD .4,5 Tau is a protein that forms part of a brain cell’s structure called a ‘microtubule.’ The microtubule helps transport nutrients within the brain cell and stabilizes the axons (a portion of a nerve cell) that connect one brain cell to another. In people with AD, Tau proteins do not function properly and form tangles inside the brain cells. This leads to a breakdown in the brain cell’s ability to communicate with other brain cells, which causes the symptoms of AD.6

Following nearly 30 years of research, researchers believe that a second-generation Tau aggregation inhibitor (TAI) could reduce the build-up of Tau tangles, and in doing so, could help slow disease progression and enhance quality of life for people with AD. Previous Phase 3 clinical trials (NCT01689233 and NCT01689246) support the possibility that this investigational treatment could be effective as a monotherapy, at a dose as low as 4 mg twice daily.7,8

Principal Investigator Dr. Laurence Radin said: “It is crucial we continue to research new targets and treatment options for Alzheimer’s disease. We are pleased to support the roll-out of the LUCIDITY study in Southeastern Connecticut, of which the results have the potential to provide renewed hope for the many people affected by this devastating disease.”

The LUCIDITY study, sponsored by TauRx Therapeutics Ltd. (“TauRx”), will evaluate the effects of this treatment in slowing or delaying memory loss in people who are not receiving other approved treatments for AD (cholinesterase inhibitors and/or memantine). Approximately 450 people in more than 100 study centers across North America and Europe are expected to take part in this study. The results of the study will help determine whether the investigational drug should progress to the final stages of clinical development.

Professor Claude Wischik, Executive Chairman and Co-Founder of TauRx, comments: “With no current cure and an aging population, Alzheimer’s disease is a pressing societal concern and there is an urgent need for new solutions. Our drug, an oral second-generation TAI, has already demonstrated encouraging signals in terms of efficacy and safety in previous trials, to the extent that it warrants further investigation. It’s our aim to find innovative and lasting solutions for patients living with Alzheimer’s disease, and we believe that Tau aggregation inhibition could be part of that solution.”

To learn more about the LUCIDITY study and to find out if you are eligible to participate, visit the trial website: LUCIDITYtrial.com or call Coastal Connecticut Research at (860)443-4567.  Information is also available at ccrstudies.com.

About Alzheimer’s disease

Alzheimer’s disease (AD) is a progressive neurologic disease of the brain that causes damage to neurons – the specialized cells of the nervous system that enable the flow of information, thoughts and memories in the brain. When Alzheimer’s damages neurons it leads to loss of memory and reasoning, which can affect a person’s ability to interact socially or function at work. No treatment yet exists to halt the progression of Alzheimer’s-related dementia, delay its onset, or prevent it from occurring. Currently available drugs only treat the symptoms temporarily.

Tau aggregation inhibitors

TauRx’s Tau aggregation inhibitors (TAIs) have arisen from nearly 30 years of research, preclinical and clinical investigations. TAIs work by undoing the Tau tangles that cause dementia, thereby potentially slowing and even arresting memory loss. The first-generation TAI, rember® was a patented, highly-purified version of methylthioninium chloride (methylene blue), a compound previously used to treat a variety of conditions.

About the LUCIDITY Study

LUCIDITY is a two-phase outpatient study with Phase 1 being a randomized, double-blind, placebo-controlled, 3-arm, 52-week safety and efficacy study and Phase 2 being an open-label, delayed start study, of an investigational drug in patients with Mild Cognitive Impairment (MCI or MCI-AD), or Probable/Early or Mild-Moderate Alzheimer’s disease. The primary objective of the LUCIDITY study is to demonstrate that the investigational treatment, given as a monotherapy at doses of 8 mg/day and 16mg/day, is effective compared to placebo in delaying the pathological and clinical progression of the disease. This will be measured using standard clinical cognitive and functional assessments; the study is expected to last up to 120 weeks for individual participants. LUCIDITY is now recruiting in sites across the United States, Canada, UK, France, Belgium, Italy, Spain and Poland. For further information, please visit: www.LUCIDITYtrial.com.

About Site

Coastal Connecticut Research in New London has partnered with community volunteers for over 20 years in conducting healthcare clinical research.  The site was founded by Dr. Robert M. Spitz who also serves as Medical Director.  In their two-decade history, 20 medications evaluated by community volunteers have gained FDA approval.

References

  1. Mavrodaris A, et al. Prevalences of dementia and cognitive impairment among older people in sub-Saharan Africa: a systematic review. Bull World Health Organ 2013, 91:773–783.
  2. World Health Organization. 2016 Dementia Fact Sheet. Available at: http://www.who.int/mediacentre/factsheets/fs362/en/ Accessed February 2019.
  3. Alzheimer’s Association. 2018 Alzheimer’s Disease Facts and Figures. Available at: https://alz.org/media/HomeOffice/Facts%20and%20Figures/facts-and-figures.pdf Accessed February 2019.
  4. Simić G, et al. Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules 2016, 6(1):6.
  5. Iqbal K, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys 2005, 1739(2-3):198–210.
  6. National Institute of Ageing. 2008 Alzheimer’s disease: Unravelling the mystery. Available at: https://adrccares.org/wp-content/uploads/2016/01/alzheimers_disease_unraveling_the_mystery_0.pdf Accessed February 2019.
  7. Gauthier S, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. The Lancet 2016, 388:2873-84.
  8. Wilcock GK, et al. Potential of Low Dose Leuco-Methylthioninium Bis (Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. Journal of Alzheimer’s Disease 2017, 61:435-457.

Media contacts:

MaryLou Gannotti

Email: marylou@ccrstudies.com

Call: (860)437-7092

Visit online: www.CCRstudies.com

LUCIDITY study website: LUCIDITYtrial.com

TauRx website: http://www.taurx.com

 

The Future of AD Research

Wednesday, September 30th, 2020

The LUCIDITY Study: A Clinical Research Study for People with Alzheimer’s disease.

Currently, a limited number of approved treatments help with the symptoms of AD, but do not stop the disease from progressing.  By reducing the build-up of ‘tau tangles,’ researchers believe that the investigational drug in this study could help slow disease progression and enhance quality of life for people with AD. The results of the LUCIDITY Study will help determine whether the investigational drug can progress to the final stages of clinical development.

The aim of the LUCIDITY Study is to assess the safety and effectiveness of an investigational drug in men and women with early to mild-moderate AD. Different doses of the investigational drug will be compared with a placebo, which looks similar to the investigational drug but contains non of its active ingredient.  Approximately 450 people in over 100 study centers across the United States, Canada, UK, France, Belgium, Italy, Spain and Poland are expected to take part.

You or a loved one may be eligible to participate in LUCIDITY if you:

  • Are under 90 years of age
  • Are experiencing memory loss, or have been diagnosed with
    • MCI (Mild Cognitive Impairment)/MCI-AD, or
    • Probable or Early Alzheimer’s disease
    • Mild-moderate Alzheimer’s disease
  • Have a study partner who can assist you with your participation

You can learn more about the LUCIDITY study by visiting http://LUCIDITYtrial.com. 

Alzheimer’s Agitation

Monday, January 22nd, 2018

Are you a stressed out caregiver? Has mom or dad become too much to handle?  Are you a spouse living with someone diagnosed with Alzheimer’s and every day is a struggle?

Agitation in Alzheimer’s disease can be unpredictable and frustrating. Symptoms can include cursing or verbal combativeness, shouting, hitting or kicking, pushing or grabbing, pacing and aimless wandering, general restlessness and more. Does this sound like your loved one?

Neurologist Dr. Laurence Radin and the CCRstudies team  are conducting the TRIAD Research Study.  Individuals with agitation due to Alzheimer’s disease along with their caregivers may be eligible to participate.  The study is evaluating and investigational medication that may help with the symptoms of Alzheimer’s agitation.  Agitation can be defined as the presence of one of more of these behavoirs:  excessive motor activity, verbal aggression, or physical aggression.

Males and females 50 to 90 years of age who have a diagnosis of probable Alzheimer’s disease may be eligible to participate.  The study has approximately 8 clinic visits over the course of 16 weeks. Reimbursement is available for time and travel.

If you know someone living at home, in an assisted living facility or in a nursing home who is living with Alzheimer’s agitation and you would like to learn more about the TRIAD Research Study, call (860) 443-4567 or email marylou@ccrstudies.com.

Alzheimer’s Agitation

Wednesday, November 22nd, 2017

The holiday season is upon us. It’s supposed to be a joyful time.  For those individuals living with or caring for someone suffering from Alzheimer’s Agitation, this can be an extremely stressful time.

Unpredictable, agitated behavior due to Alzheimer’s disease can be frustrating and overwhelming for people who have a loved on in their life living with these symptoms. Wandering, pacing, screaming, swearing and hitting can be extremely unsettling symptoms of Alzheimer’s.  People unfamiliar with Alzheimer’s sometimes think memory loss is the only part of Alzheimer’s that affects people.  This is not so.

Alzheimer’s agitation can be disruptive, unpredictable and potentially harmful to people.  Physical and verbal aggression are among the most common expressions of this condition.

Research is underway in New London and nationwide testing an investigational medication to see if it may reduce the symptoms of agitation due to Alzheimer’s disease.  New London Neurologist Dr. Laurence Radin and Andrea Stewart APRN are among the study investigators. There are 8 office visits during the course of the approximately 16 week study.

If you have concerns regarding a loved one’s Alzheimer’s Agitation and you are interested in learning more about this research study, please contact a member of the CCRstudies team at (860) 443-4567.  Research nurses are Qualified Dementia Care Specialists who will be able to provide further information.

November is Alzheimer’s Awareness Month

Thursday, November 2nd, 2017

 

CCRstudies is a member of the Alzheimer’s Foundation of America.

November is national Alzheimer’s Awareness Month.

Here at Coastal Connecticut Research, we’ve been heavily involved in the fight against Alzheimer’s.  We have conducted a variety of Alzheimer’s clinical research studies with primary investigator Dr. Laurence Radin, who specializes in neurology.  We have also provided community members with no cost memory screenings

as a public service through the Alzheimer’s Foundation of America’s early detection program.  To date, over 100 no cost screenings have been offered to the public through our Mobile Memory Clinics.

Over 5 million Americans are living with Alzheimer’s disease, a progressive, degenerative condition.  Research will continue to help discover and  develop improved treatments for individuals living with memory loss.

If you or someone you know is living with memory loss, has a family history of memory loss, or would like to learn more about research involving memory loss, call to speak to a member of the CCRstudies team at (860) 443-4567 or email marylou@ccrstudies.com. 

 

No Cost Memory Screenings, Total Life Expo

Thursday, October 19th, 2017

For the second consecutive year Coastal Connecticut Research will be offering no cost memory screenings at the Eastern Connecticut Chamber of Commerce’s Total Life Expo. This massive health fair and vendor exhibition takes place at Mohegan Sun Casino on Saturday, October 21st from 10 am until 2pm.

We are proud to be associate members of the Alzheimer’s Foundation of America enabling us to help fight memory disease through early detection.

Get your no cost “check up from the neck up.”  Think of it as a healthy brain check up!  Can’t make it to the Sun?  Give us a call in our office for your evaluation at 860-443-4567. Our nurses are trained dementia care specialists and we look forward to hearing from you.

Concerned about mild memory or possible Alzheimer’s?  Does a family member have dementia?  (860) 443-4567.

Migraine Headaches

Thursday, May 25th, 2017

For years, Susan had been living with incapacitating headaches that sometimes caused her to miss work or family events.  The headaches began in her late teens and have lasted until now, her mid-30’s.  Sometimes the headaches would start on a Monday and stretch all the way until Wednesday.  Quite frequently with these headaches Susan would experience nausea, as well as sensitivity to lights and sounds.  When these headaches came on, Susan would turn off all the lights, avoid people and hunker down.  What Susan did not realize is her headaches were in fact migraines!

Not everyone who lives with migraine headaches realize they are in fact getting a migraine.  3 million Americans are currently suffering with this condition.  Vision can become blurred, people can experience fatigue, stomach upset, and intense, throbbing pain.

Research is underway in New London testing an investigational medication for the prevention of migraine headaches. Dr. Laurence Radin, Dr. Edward McDermott, and Andrea Stewart APRN are members of a  Migraine Prevention Study  research team in New London. Individuals living with migraine headaches who may wish to learn more about this 9-month research study are welcome to call to speak with a member of the CCRstudies team at (860) 443-4567 or email marylou@ccrstudies.com.